139 related articles for article (PubMed ID: 34994597)
61. Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma.
Ock CY; Son B; Keam B; Lee SY; Moon J; Kwak H; Kim S; Kim TM; Jeon YK; Kwon SK; Hah JH; Lee SH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
J Cancer Res Clin Oncol; 2016 Apr; 142(4):873-83. PubMed ID: 26677030
[TBL] [Abstract][Full Text] [Related]
62. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
63. Germline variants in DNA repair genes are associated with young-onset head and neck cancer.
Cury SS; Miranda PM; Marchi FA; Canto LMD; Chulam TC; Petersen AH; Aagaard MM; Pinto CAL; Kowalski LP; Rogatto SR
Oral Oncol; 2021 Nov; 122():105545. PubMed ID: 34598035
[TBL] [Abstract][Full Text] [Related]
64. Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets.
Iglesias-Bartolome R; Martin D; Gutkind JS
Cancer Discov; 2013 Jul; 3(7):722-5. PubMed ID: 23847349
[TBL] [Abstract][Full Text] [Related]
65. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
66. Genomic landscape and tumor mutation burden analysis of Chinese patients with sarcomatoid carcinoma of the head and neck.
Chen HB; Gong XY; Li W; Chen DS; Zhao LL; Li S; Xiao MZ; Cheng L; Chen X
Oral Oncol; 2021 Oct; 121():105436. PubMed ID: 34371452
[TBL] [Abstract][Full Text] [Related]
67. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.
Tinhofer I; Budach V; Saki M; Konschak R; Niehr F; Jöhrens K; Weichert W; Linge A; Lohaus F; Krause M; Neumann K; Endris V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baumann M;
Eur J Cancer; 2016 Apr; 57():78-86. PubMed ID: 26896955
[TBL] [Abstract][Full Text] [Related]
68. Delineating genetic pathways of disease progression in head and neck squamous cell carcinoma.
Worsham MJ; Pals G; Schouten JP; Van Spaendonk RM; Concus A; Carey TE; Benninger MS
Arch Otolaryngol Head Neck Surg; 2003 Jul; 129(7):702-8. PubMed ID: 12874067
[TBL] [Abstract][Full Text] [Related]
69. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
70. MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel
Chu LP; Franck D; Parachoniak CA; Gregg JP; Moore MG; Farwell DG; Rao S; Heilmann AM; Erlich RL; Ross JS; Miller VA; Ali S; Riess JW
Oncologist; 2019 Oct; 24(10):1305-1308. PubMed ID: 31391294
[TBL] [Abstract][Full Text] [Related]
71. Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients.
Melisi D; Cavaliere A; Gobbo S; Fasoli G; Allegrini V; Simionato F; Gaule M; Casalino S; Pesoni C; Zecchetto C; Merz V; Mambrini A; Barbi E; Girelli R; Giardino A; Frigerio I; Scalamogna R; Avitabile A; Castellani S; Milella M; Butturini G
Pancreatology; 2021 Apr; ():. PubMed ID: 33896692
[TBL] [Abstract][Full Text] [Related]
72. Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience.
Porta C; Pradelli L; Sicari E; Castellani S; Sivakumar S; Sokol E; Montesion M; Wieland T; Rambichler J; Minari R; Tiseo M
Lung Cancer; 2023 Nov; 185():107359. PubMed ID: 37703610
[TBL] [Abstract][Full Text] [Related]
73. Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC).
Shu L; Wang D; Nannapaneni S; Sun Y; Griffith CC; Wang X; Chen Z; Patel M; El-Deiry M; Shin DM; Chen ZG; Saba NF
Oral Oncol; 2021 Nov; 122():105546. PubMed ID: 34700281
[TBL] [Abstract][Full Text] [Related]
74. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
75. The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
Chen TC; Wu CT; Wang CP; Lou PJ; Ko JY; Chang YL
Oral Oncol; 2020 Dec; 111():104945. PubMed ID: 32769036
[TBL] [Abstract][Full Text] [Related]
76. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
[TBL] [Abstract][Full Text] [Related]
77. BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.
Leonard B; Brand TM; O'Keefe RA; Lee ED; Zeng Y; Kemmer JD; Li H; Grandis JR; Bhola NE
Cancer Res; 2018 Aug; 78(15):4331-4343. PubMed ID: 29792310
[TBL] [Abstract][Full Text] [Related]
78. Search for mutations in signaling pathways in head and neck squamous cell carcinoma.
De Carvalho TG; De Carvalho AC; Maia DC; Ogawa JK; Carvalho AL; Vettore AL
Oncol Rep; 2013 Jul; 30(1):334-40. PubMed ID: 23670291
[TBL] [Abstract][Full Text] [Related]
79. [Genomic characterization of head and neck squamous cell carcinoma: Impact and challenges for therapeutic management].
Saada-Bouzid E; Milano G; Thariat J
Bull Cancer; 2018 Sep; 105(9):820-829. PubMed ID: 29937334
[TBL] [Abstract][Full Text] [Related]
80. Integrative Analysis of Multi-omics Data Identified EGFR and PTGS2 as Key Nodes in a Gene Regulatory Network Related to Immune Phenotypes in Head and Neck Cancer.
Feng B; Shen Y; Pastor Hostench X; Bieg M; Plath M; Ishaque N; Eils R; Freier K; Weichert W; Zaoui K; Hess J
Clin Cancer Res; 2020 Jul; 26(14):3616-3628. PubMed ID: 32161122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
